B.A. (1974) – Southern Methodist University, Texas (Chemistry)
M.D. (1978) – University of Texas, Southwestern Medical School
Residency (1978-81) – Massachusetts General Hospital (Internal Medicine)
University of Texas, Southwestern Medical School (Clinical Nephrology)
Postdoctoral Fellow (1982-84) – University of Texas, Southwestern Medical School, (Department of Molecular Genetics)
Formerly Hakim Professor of Medicine and Cell Biology at Vanderbilt University, Thomas O. Daniel practiced nephrology, founded translational research efforts in the Vanderbilt Ingram Cancer Center, co-directed the MD/PhD program, funded and led research efforts defining molecular determinants of endothelial function, and served on numerous NIH and other national funding committees.
In 2000, Dr. Daniel joined Immunex Corporation as Sr. Vice President, Research. There he built an oncology research division, enabled therapeutic antibody capability, and advanced collaborations leading to development of panitumumab (Vectibix).
As Vice President of Research at Amgen, he led the Inflammation Therapeutic Area and headed the Seattle research site, advancing etanercept (Enbrel) into new indications, flt3-L, and several anti-angiogenic programs.
In 2003, Dr. Daniel joined founders as Chief Scientific Officer and Director of Ambrx, a venture backed start-up deploying a novel platform technology for enhancing performance of protein therapeutics. At Ambrx, the team he built advanced its first drug candidate into clinical testing within 3 years, raised multiple rounds of venture funding, and created projects partnered with 4 pharma collaborators.
Doctor Daniel joined Celgene in late 2006, formulating and executing on a strategy that has yielded a robust and diversified pipeline in oncology and immune-inflammatory diseases, including 4 new INDs and to address serious unmet medical need.
Doctor Daniel has served on the National Academy of Sciences/National Research Council NIH Committee on Manpower Planning, chaired the 2008 Gordon Research Conference on Endothelial Phenotypes in Disease, and currently serves on the Boards of Directors for Ferrumax Corporation and Carbon Capture Corporation, and the Vanderbilt Biomedical Science Advisory Board.
Doctor Daniel is a graduate of UT Southwestern Medical School, completed medical residency at Massachusetts General Hospital, trained in Molecular Genetics with Nobelists Michael Brown and Joseph Goldstein, was a Howard Hughes Medical Institute Associate and recipient of over 20 years of NIH research funding.